![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Flexion’s Zilretta Shows Positive Results in Phase 3 Trial
Flexion’s Zilretta Shows Positive Results in Phase 3 Trial
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/KeytoSuccess.gif?t=1474505946&width=430)
February 23, 2016
Flexion Therapeutics’ osteoarthritis candidate Zilretta shined in a Phase 3 study, meeting its primary endpoint of statistically significant pain relief at week 12 compared with placebo.
Patients treated with Zilretta experienced on average a 50 percent reduction in pain from baseline against placebo. No serious drug-related adverse events were observed during the trial.
Upcoming Events
-
21Oct